In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bruce Thompson, CEO of Kincell Bio.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bruce, covering:
The daunting and exciting prospect of launching a CDMO spin-out focused on early-phase companies
The challenges and opportunities of pivoting a facility from innovator-owned to CDMO-owned
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bruce Thompson, CEO of Kincell Bio.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bruce, covering:
- The daunting and exciting prospect of launching a CDMO spin-out focused on early-phase companies
- The challenges and opportunities of pivoting a facility from innovator-owned to CDMO-owned
- Navigating from technical leader to a first CEO role... and the importance of covering your blind spots
- Why Bruce is seeing an upturn in the market and the emergence of more diverse opportunities.
Bruce is the CEO of Kincell Bio, bringing over 28 years of experience to his position. Before this, he was Vice President and Technical Lead for the Cell Therapy Franchise at Resilience, Inc., where he helped build the development and GMP manufacturing capabilities and served as a technical advisor internally and externally.
He has over 18 years of CMC strategy, product development, and cell therapy manufacturing experience. In his first startup role, he was Vice President of Process Sciences at Lyell Immunopharma, where he was responsible for Process and Analytical Development and tech transfer of processes and methods to a newly built state-of-the-art cGMP facility. Prior to Lyell, Bruce served as the Sr. Director of the Therapeutic Products Program at Fred Hutchinson Cancer Research Center (FHCRC), where he led GMP manufacturing of cell and gene therapy products. He was responsible for supporting >15 active clinical programs and contributed to the filing of 6 INDs for various cell therapy programs.
Bruce also spent nearly ten years at Pfizer in the Pharmaceutical Sciences division, and he received his B.A. in Biology, an M.S. in Biochemistry from The Ohio State University, and a Ph.D. in Microbiology and Immunology from the University of Louisville.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.
View more
